SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Nov 8, 2018–Veracyte, Inc. (Nasdaq: VCYT) appear today the advertisement of “real world” abstracts assuming that the Afirma® Genomic Sequencing Classifier (GSC) enables alike added patients to abstain accidental anaplasty in thyroid blight analysis compared to the company’s flagship, aboriginal Afirma Gene Expression Classifier (GEC). The allegation are appear online in , the account of the American Association of Analytic Endocrinologists.
20 Anderson Trailers Anderson 20×20 Landscape Utility Trailer .. | anderson utility products
Image Source: azureedge.net
In the study, advisers from Memorial Healthcare Arrangement in Hollywood, Fla., advised abstracts from all patients in their convenance whose thyroid nodules were accounted general (i.e., not acutely amiable or cancerous) by cytopathology analysis and who after accustomed after-effects from genomic testing with the Afirma GSC (n=139) or the Afirma GEC (n=481). They begin that the Afirma GSC articular 47 percent added thyroid nodules as amiable than the first-generation analysis (61.2 percent vs. 41.6 percent). Use of the next-generation analysis additionally bargain all-embracing anaplasty ante amid all patients with general thyroid nodules by 45 percent. The advisers bent that acuteness for the Afirma GSC in their convenance was 97 percent.
The RNA sequencing-based Afirma GSC approved abnormally able achievement in appropriate amiable from annihilative Hürthle beef – a class of thyroid corpuscle that has historically been arduous to analyze by cytopathology or atomic methods. The Afirma GSC articular 64.7 percent of Hürthle corpuscle ascendant biopsies as amiable compared to 17.3 percent with the aboriginal analysis and badly bargain all-embracing anaplasty referrals in this accumulation by 57.3 percent.
“Our abstracts advance that the Afirma GSC is allowance us to added abate accidental surgeries amid our patients with general thyroid nodules by acceptable the aboriginal test’s specificity while advancement its aerial sensitivity,” said R. Mack Harrell, M.D., cofounder of the Memorial Center for Integrative Endocrine Anaplasty and advance columnist of the new study. “A key acumen for this change is the Afirma GSC’s adeptness to aphorism out blight in Hürthle-dominant thyroid nodules. This is important because Hürthle-dominant cases comprise 22 percent of the general thyroid nodules we evaluate.”
Dr. Harrell’s convenance began application the Afirma GEC back it was alien in January 2011. They accept been alms patients the Afirma GSC back it became accessible in August 2017.
“This new advertisement adds to the growing anatomy of real-world abstracts acknowledging the account and constant achievement of the Afirma GSC beyond a array of analytic settings,” said Bonnie Anderson, Veracyte’s administrator and arch controlling officer. “Developed application a atypical aggregate of RNA sequencing and apparatus acquirements technology, the Afirma GSC helps alike added patients with amiable thyroid nodules get clearer answers and abstain accidental surgery, added benefitting them, their physicians and the healthcare system.”
Veracyte’s Afirma band-aid provides a absolute alms in thyroid blight analysis for physicians evaluating patients with thyroid nodules. The Afirma Genomic Sequencing Classifier combines RNA sequencing abstracts with apparatus acquirements to analyze patients with amiable thyroid nodules amid those with general cytopathology after-effects in adjustment to abstain accidental anaplasty and bottle the thyroid. Back the bartering addition of Afirma in 2011, Veracyte has performed over 100,000 genomic tests, and estimates it has adored added than 40,000 patients from accidental thyroid anaplasty and removed an estimated $800 actor in anaplasty costs from the healthcare system. The Afirma classifier is accurate in over 20 appear analytic studies, is included in best arch analytic guidelines and is covered as medically all-important by Medicare and all above U.S. bloom plans. The company’s Afirma Xpression Atlas platform, alien in May 2018, provides all-encompassing genomic abstracts that may acquaint anaplasty action and analysis options for patients with thyroid nodules that are apprehensive for blight or cancerous. The RNA sequencing-based belvedere measures 761 DNA variants and 130 RNA fusions in over 500 genes apparent to be associated with thyroid blight on thyroid birthmark accomplished aggravate aspiration samples.
Veracyte (Nasdaq: VCYT) is a arch genomic affection aggregation that improves accommodating affliction by accouterment accurate and actionable answers to arduous analytic questions. The company’s articles abnormally amalgamate avant-garde genomic technology, analytic science and apparatus acquirements to accommodate answers that accord physicians and patients a bright aisle forward, allegorical both analysis and analysis decisions after the charge for costly, chancy surgeries that are generally unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the analysis of thyroid cancer, lung blight and idiopathic pulmonary fibrosis and collectively ambition a $2 billion bazaar opportunity. Veracyte is based in South San Francisco, California. For added information, amuse appointment www.veracyte.com and chase the aggregation on Twitter (@veracyte).
Cautionary Note Apropos Forward-Looking Statements
This columnist absolution contains “forward-looking statements” aural the acceptation of the Private Securities Litigation Reform Act of 1995. Advanced statements can be articular by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will” and agnate references to approaching periods. Examples of advanced statements include, amid others, our acceptance apropos the capability of the Afirma GSC. Advanced statements are neither absolute facts nor assurances of approaching performance. Instead, they are based alone on our accepted beliefs, expectations and assumptions apropos the approaching of our business, approaching affairs and strategies, advancing contest and trends, the abridgement and added approaching conditions. Advanced statements absorb risks and uncertainties, which could account absolute after-effects to alter materially, and appear after-effects should not be advised as an adumbration of approaching performance. These risks and uncertainties include, but are not bound to: our adeptness to accomplish Medicare advantage for our tests, the bazaar befalling for the Envisia classifier, the allowances of our tests, the account of analytic after-effects to absolute outcomes; the laws and regulations applicative to our business, including abeyant adjustment by the Food and Drug Administration or added authoritative bodies; our adeptness to advertise our Afirma tests and auspiciously alteration to our next-generation Afirma GSC; our adeptness to auspiciously accomplish and advance acceptance of and agreement for our products; the bulk by which use of our articles are able to abate invasive procedures and misdiagnosis, and abate healthcare costs; the accident and outcomes of analytic studies; and added risks set alternating in our filings with the Securities and Exchange Commission, including the risks set alternating in our annual address on Form 10-Q for the division ended September 30, 2018. These advanced statements allege alone as of the date hereof and Veracyte specifically disclaims any obligation to amend these advanced statements or affidavit why absolute after-effects ability differ, whether as a aftereffect of new information, approaching contest or otherwise, except as appropriate by law.
Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.
View antecedent adaptation on businesswire.com:https://www.businesswire.com/news/home/20181108005995/en/
CONTACT: Veracyte Media & Investor Contact:
Angie McCabe, 650-243-6371
Vice President, Investor Relations & Corporate Communications
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY MEDICAL DEVICES ONCOLOGY GENERAL HEALTH
Copyright Business Wire 2018.
PUB: 11/08/2018 04:24 PM/DISC: 11/08/2018 04:24 PM
Copyright Business Wire 2018.
How To Leave Anderson Utility Products Without Being Noticed | anderson utility products – anderson utility products
| Delightful to be able to the website, in this time I am going to show you with regards to keyword. And today, this can be the primary image:
Other Collections of How To Leave Anderson Utility Products Without Being Noticed | anderson utility products